The role of uroselective α1AAR antagonists in the treatment of BPH

The role of uroselective α1AAR antagonists in the treatment of BPH

The role of uroselective α1AAR antagonists in the treatment of BPH

Urology
A badge with ribbon in color black Point(s): 1 | An analog clock in color black 20 minutes | A black calendar with white triangle in center that has a black exclamation point in the middle 19 Feb 2022 

Overview

NEW!

The goal of this learning activity is to provide doctors with a comprehensive review of the impact of subtype-selective α1-adrenergic receptor ( α1AR) antagonists in the treatment of benign prostatic hyperplasia (BPH). 

Upon completing this module, participants will have a better understanding of the following aspects:
• Epidemiology of BPH
• Pathophysiology of BPH
• Evaluation and management of lower urinary tract symptoms (LUTS)
• Safety and efficacy of selective α1AAR antagonists 

CPD Reviewer:

Professor Dr Ong Teng Aik

Head of the Division of Urology

University Malaya Medical Centre


NOTE :
Please read thoroughly & understand the module before attempting the assessment questions.

Terms & Conditions: 
■ Participants must obtain a minimum score of 8/10 (80%) to be awarded 1 point. 
■ MIMS Education and MIMS Medica shall not be responsible or liable for the outcome of your CPD points. 

The modules/articles are best viewed with:

Google Chrome, Firefox, Internet Explorer, Safari or any other W3C standards compliant browser may be required to view the modules.


Sponsored by:

Eisai_logo.jpg